The potential to backfill in phase I trials: the National Cancer Institute's Cancer Therapy Evaluation Program experience
JNCI Cancer Spectr
.
2023 Oct 31;7(6):pkad102.
doi: 10.1093/jncics/pkad102.
Authors
Jared C Foster
1
,
Edward L Korn
1
,
Boris Freidlin
1
,
Jeffrey A Moscow
2
Affiliations
1
Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
2
Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
PMID:
38001028
PMCID:
PMC10727837
DOI:
10.1093/jncics/pkad102
No abstract available
Publication types
Clinical Trial, Phase I
MeSH terms
Humans
National Cancer Institute (U.S.)
Neoplasms* / therapy
Research Design*
United States